Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib

Annals of Hematology

Volumn 93, Issue 12, 2014, Pages 2087-2089

  Vergote, V ^a   Dierickx, D ^a   Janssens, A ^a   Verhoef, G ^a   Tousseyn, T ^a   Vandenberghe, P ^a   Wolter, P ^a   Delforge, M ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; B RAF KINASE; BRAF PROTEIN, HUMAN; CLADRIBINE; DABRAFENIB; IMIDAZOLE DERIVATIVE; MONOCLONAL ANTIBODY; OXIME; PROTEIN KINASE INHIBITOR; RITUXIMAB; TUMOR PROTEIN;

ANTAGONISTS AND INHIBITORS; BLOOD; CASE REPORT; CHEMICALLY INDUCED; COMPASSIONATE USE; COMPLICATION; DRUG RESISTANCE; GENETICS; HUMAN; LEUKEMIA, HAIRY CELL; MALE; MIDDLE AGED; MISSENSE MUTATION; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; POINT MUTATION; PULMONARY ASPERGILLOSIS; REMISSION; SALVAGE THERAPY; SPLENECTOMY;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CLADRIBINE; COMBINED MODALITY THERAPY; COMPASSIONATE USE TRIALS; DRUG RESISTANCE, NEOPLASM; HUMANS; IMIDAZOLES; LEUKEMIA, HAIRY CELL; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION, MISSENSE; NEOPLASM PROTEINS; NEUTROPENIA; OXIMES; POINT MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PULMONARY ASPERGILLOSIS; REMISSION INDUCTION; SALVAGE THERAPY; SPLENECTOMY;

EID: 84922240714     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2104-2     Document Type: Letter

References (11)

1. Tiacci E, Trifonov V, Schiavoni G et al (2011) BRAF mutations in hairy-cell leukemia. N Engl J Med 364:2305–2315
2. Dietrich S, Glimm H, Andrulis M et al (2012) BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 366:2038–2040
3. Follows G, Sims H, Bloxham D et al (2013) Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib. Br J Haematol 161:150–153
4. Munoz J, Schlette E, Kurzrock R (2013) Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. J Clin Oncol 31:e351–e352
5. Dietrich S, Hüllein S, Hundemer M et al (2013) Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia. J Clin Oncol 31:e300–e303
6. Maurer H, Haas P, Wengenmayer T, Lübbert M, Duyster J, Zeiser R. Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosis. Ann Hematol. 2013; Dec 14. [Epub ahead of print]
7. Peyrade F, Re D, Ginet C et al (2013) Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation. Haematologica 98:e20–e22
8. Grever MR (2010) How I, treat hairy cell leukemia. Blood 115(1):21–28
9. Jang S, Atkins MB (2013) Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol 14(2):e60–e69. doi:10.1016/S1470-2045(12)70539-9
10. Andritsos L, Blachly J, Kendra K, Lozanski G, Grever M (2013) Co-treatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib. Blood 122:5311
11. Anforth R, Fernandez-Peñas P, Long GV (2013) Cutaneous toxicities of RAF inhibitors. Lancet Oncol 14(1):e11–e18